Cargando…
Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID‐19 Clinical Trials
Azithromycin (AZ), a broad‐spectrum macrolide antibiotic, is being investigated in patients with coronavirus disease 2019 (COVID‐19). A population pharmacokinetic model was implemented to predict lung, intracellular poly/mononuclear cell (peripheral blood monocyte (PBM)/polymorphonuclear leukocyte (...
Autores principales: | Hughes, Jim H., Sweeney, Kevin, Ahadieh, Sima, Ouellet, Daniele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300789/ https://www.ncbi.nlm.nih.gov/pubmed/32511867 http://dx.doi.org/10.1002/psp4.12537 |
Ejemplares similares
-
Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma
por: Scheibenpflug, Raphael, et al.
Publicado: (2021) -
Azithromycin effectiveness against intracellular infections of Francisella
por: Ahmad, Saira, et al.
Publicado: (2010) -
Relative effectiveness of azithromycin in killing intracellular Porphyromonas gingivalis
por: Lai, Pin‐Chuang, et al.
Publicado: (2016) -
Biannual Treatment of Preschool Children with Single Dose Azithromycin to Reduce Mortality: Impact on Azithromycin Resistance in the MORDOR Trial in Tanzania
por: Bloch, Evan M., et al.
Publicado: (2020) -
Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of helicobacter pylori: A randomized clinical trial
por: Khoshnood, A, et al.
Publicado: (2014)